ARQT Average Annual Return Since 2020
Growth of $10,000.00
Without Dividends Reinvested Into ARQT


Also see:
ARQT stock yearly return 2021
ARQT stock yearly return 2022
ARQT stock yearly return 2023
ARQT YTD return
Compare ARQT average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 02/03/2020
End date: 06/14/2024
Start price/share: $25.13
End price/share: $8.63
Dividends collected/share: $0.00
Total return: -65.66%
ARQT Average Annual Return: -21.73%
Starting investment: $10,000.00
Ending investment: $3,434.79
Years: 4.36


ARQT average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Arcutis Biotherapeutics is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. Co.'s primary product candidate, roflumilast cream, has the potential to provide symptomatic improvement in psoriasis patients similar to the combination of a high potency steroid and calcipotriene, a tolerability profile, the ability to be used chronically, and little to none of the application site reactions associated with various existing topical treatments. Co. is also developing a foam formulation of topical roflumilast for the treatment of scalp psoriasis and seborrheic dermatitis. The ARQT average annual return since 2020 is shown above.

The Average Annual Return on the ARQT average annual return since 2020 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether ARQT average annual return since 2020 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the ARQT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree ARQT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Arcutis Biotherapeutics (ARQT) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

ARTL Average Annual Return
ARVN Average Annual Return
ARWR Average Annual Return
ASMB Average Annual Return
ASPI Average Annual Return
ASRT Average Annual Return
ASTH Average Annual Return
ATEC Average Annual Return
ATHA Average Annual Return
ATIP Average Annual Return
More Healthcare companies »

 

ARQT Average Annual Return Since 2020 | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.